Copyright Reports & Markets. All rights reserved.

Global Empagliflozin and Metformin Hydrochloride Tablets Market 2026 by Manufacturers, Regions, Type and Application, Forecast to 2032

Request for Sample of this report
Buy now

1 Market Overview

  • 1.1 Product Overview and Scope
  • 1.2 Market Estimation Caveats and Base Year
  • 1.3 Market Analysis by Type
    • 1.3.1 Overview: Global Empagliflozin and Metformin Hydrochloride Tablets Consumption Value by Type: 2021 Versus 2025 Versus 2032
    • 1.3.2 Immediate-release (IR)
    • 1.3.3 Sustained-release (SR)
  • 1.4 Market Analysis by Dosage Form
    • 1.4.1 Overview: Global Empagliflozin and Metformin Hydrochloride Tablets Consumption Value by Dosage Form: 2021 Versus 2025 Versus 2032
    • 1.4.2 Tablets
    • 1.4.3 Powder
  • 1.5 Market Analysis by Production Technology
    • 1.5.1 Overview: Global Empagliflozin and Metformin Hydrochloride Tablets Consumption Value by Production Technology: 2021 Versus 2025 Versus 2032
    • 1.5.2 Innovator Drug
    • 1.5.3 Generic Drug
  • 1.6 Market Analysis by Application
    • 1.6.1 Overview: Global Empagliflozin and Metformin Hydrochloride Tablets Consumption Value by Application: 2021 Versus 2025 Versus 2032
    • 1.6.2 Type 2 Diabetes Mellitus
    • 1.6.3 Cardiovascular
    • 1.6.4 Renal Protection
    • 1.6.5 Others
  • 1.7 Global Empagliflozin and Metformin Hydrochloride Tablets Market Size & Forecast
    • 1.7.1 Global Empagliflozin and Metformin Hydrochloride Tablets Consumption Value (2021 & 2025 & 2032)
    • 1.7.2 Global Empagliflozin and Metformin Hydrochloride Tablets Sales Quantity (2021-2032)
    • 1.7.3 Global Empagliflozin and Metformin Hydrochloride Tablets Average Price (2021-2032)

2 Manufacturers Profiles

  • 2.1 Boehringer Ingelheim
    • 2.1.1 Boehringer Ingelheim Details
    • 2.1.2 Boehringer Ingelheim Major Business
    • 2.1.3 Boehringer Ingelheim Empagliflozin and Metformin Hydrochloride Tablets Product and Services
    • 2.1.4 Boehringer Ingelheim Empagliflozin and Metformin Hydrochloride Tablets Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.1.5 Boehringer Ingelheim Recent Developments/Updates
  • 2.2 Eli Lilly and Company
    • 2.2.1 Eli Lilly and Company Details
    • 2.2.2 Eli Lilly and Company Major Business
    • 2.2.3 Eli Lilly and Company Empagliflozin and Metformin Hydrochloride Tablets Product and Services
    • 2.2.4 Eli Lilly and Company Empagliflozin and Metformin Hydrochloride Tablets Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.2.5 Eli Lilly and Company Recent Developments/Updates
  • 2.3 Lupin Limited
    • 2.3.1 Lupin Limited Details
    • 2.3.2 Lupin Limited Major Business
    • 2.3.3 Lupin Limited Empagliflozin and Metformin Hydrochloride Tablets Product and Services
    • 2.3.4 Lupin Limited Empagliflozin and Metformin Hydrochloride Tablets Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.3.5 Lupin Limited Recent Developments/Updates
  • 2.4 Kureasia Pharma
    • 2.4.1 Kureasia Pharma Details
    • 2.4.2 Kureasia Pharma Major Business
    • 2.4.3 Kureasia Pharma Empagliflozin and Metformin Hydrochloride Tablets Product and Services
    • 2.4.4 Kureasia Pharma Empagliflozin and Metformin Hydrochloride Tablets Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.4.5 Kureasia Pharma Recent Developments/Updates

3 Competitive Environment: Empagliflozin and Metformin Hydrochloride Tablets by Manufacturer

  • 3.1 Global Empagliflozin and Metformin Hydrochloride Tablets Sales Quantity by Manufacturer (2021-2026)
  • 3.2 Global Empagliflozin and Metformin Hydrochloride Tablets Revenue by Manufacturer (2021-2026)
  • 3.3 Global Empagliflozin and Metformin Hydrochloride Tablets Average Price by Manufacturer (2021-2026)
  • 3.4 Market Share Analysis (2025)
    • 3.4.1 Producer Shipments of Empagliflozin and Metformin Hydrochloride Tablets by Manufacturer Revenue ($MM) and Market Share (%): 2025
    • 3.4.2 Top 3 Empagliflozin and Metformin Hydrochloride Tablets Manufacturer Market Share in 2025
    • 3.4.3 Top 6 Empagliflozin and Metformin Hydrochloride Tablets Manufacturer Market Share in 2025
  • 3.5 Empagliflozin and Metformin Hydrochloride Tablets Market: Overall Company Footprint Analysis
    • 3.5.1 Empagliflozin and Metformin Hydrochloride Tablets Market: Region Footprint
    • 3.5.2 Empagliflozin and Metformin Hydrochloride Tablets Market: Company Product Type Footprint
    • 3.5.3 Empagliflozin and Metformin Hydrochloride Tablets Market: Company Product Application Footprint
  • 3.6 New Market Entrants and Barriers to Market Entry
  • 3.7 Mergers, Acquisition, Agreements, and Collaborations

4 Consumption Analysis by Region

  • 4.1 Global Empagliflozin and Metformin Hydrochloride Tablets Market Size by Region
    • 4.1.1 Global Empagliflozin and Metformin Hydrochloride Tablets Sales Quantity by Region (2021-2032)
    • 4.1.2 Global Empagliflozin and Metformin Hydrochloride Tablets Consumption Value by Region (2021-2032)
    • 4.1.3 Global Empagliflozin and Metformin Hydrochloride Tablets Average Price by Region (2021-2032)
  • 4.2 North America Empagliflozin and Metformin Hydrochloride Tablets Consumption Value (2021-2032)
  • 4.3 Europe Empagliflozin and Metformin Hydrochloride Tablets Consumption Value (2021-2032)
  • 4.4 Asia-Pacific Empagliflozin and Metformin Hydrochloride Tablets Consumption Value (2021-2032)
  • 4.5 South America Empagliflozin and Metformin Hydrochloride Tablets Consumption Value (2021-2032)
  • 4.6 Middle East & Africa Empagliflozin and Metformin Hydrochloride Tablets Consumption Value (2021-2032)

5 Market Segment by Type

  • 5.1 Global Empagliflozin and Metformin Hydrochloride Tablets Sales Quantity by Type (2021-2032)
  • 5.2 Global Empagliflozin and Metformin Hydrochloride Tablets Consumption Value by Type (2021-2032)
  • 5.3 Global Empagliflozin and Metformin Hydrochloride Tablets Average Price by Type (2021-2032)

6 Market Segment by Application

  • 6.1 Global Empagliflozin and Metformin Hydrochloride Tablets Sales Quantity by Application (2021-2032)
  • 6.2 Global Empagliflozin and Metformin Hydrochloride Tablets Consumption Value by Application (2021-2032)
  • 6.3 Global Empagliflozin and Metformin Hydrochloride Tablets Average Price by Application (2021-2032)

7 North America

  • 7.1 North America Empagliflozin and Metformin Hydrochloride Tablets Sales Quantity by Type (2021-2032)
  • 7.2 North America Empagliflozin and Metformin Hydrochloride Tablets Sales Quantity by Application (2021-2032)
  • 7.3 North America Empagliflozin and Metformin Hydrochloride Tablets Market Size by Country
    • 7.3.1 North America Empagliflozin and Metformin Hydrochloride Tablets Sales Quantity by Country (2021-2032)
    • 7.3.2 North America Empagliflozin and Metformin Hydrochloride Tablets Consumption Value by Country (2021-2032)
    • 7.3.3 United States Market Size and Forecast (2021-2032)
    • 7.3.4 Canada Market Size and Forecast (2021-2032)
    • 7.3.5 Mexico Market Size and Forecast (2021-2032)

8 Europe

  • 8.1 Europe Empagliflozin and Metformin Hydrochloride Tablets Sales Quantity by Type (2021-2032)
  • 8.2 Europe Empagliflozin and Metformin Hydrochloride Tablets Sales Quantity by Application (2021-2032)
  • 8.3 Europe Empagliflozin and Metformin Hydrochloride Tablets Market Size by Country
    • 8.3.1 Europe Empagliflozin and Metformin Hydrochloride Tablets Sales Quantity by Country (2021-2032)
    • 8.3.2 Europe Empagliflozin and Metformin Hydrochloride Tablets Consumption Value by Country (2021-2032)
    • 8.3.3 Germany Market Size and Forecast (2021-2032)
    • 8.3.4 France Market Size and Forecast (2021-2032)
    • 8.3.5 United Kingdom Market Size and Forecast (2021-2032)
    • 8.3.6 Russia Market Size and Forecast (2021-2032)
    • 8.3.7 Italy Market Size and Forecast (2021-2032)

9 Asia-Pacific

  • 9.1 Asia-Pacific Empagliflozin and Metformin Hydrochloride Tablets Sales Quantity by Type (2021-2032)
  • 9.2 Asia-Pacific Empagliflozin and Metformin Hydrochloride Tablets Sales Quantity by Application (2021-2032)
  • 9.3 Asia-Pacific Empagliflozin and Metformin Hydrochloride Tablets Market Size by Region
    • 9.3.1 Asia-Pacific Empagliflozin and Metformin Hydrochloride Tablets Sales Quantity by Region (2021-2032)
    • 9.3.2 Asia-Pacific Empagliflozin and Metformin Hydrochloride Tablets Consumption Value by Region (2021-2032)
    • 9.3.3 China Market Size and Forecast (2021-2032)
    • 9.3.4 Japan Market Size and Forecast (2021-2032)
    • 9.3.5 South Korea Market Size and Forecast (2021-2032)
    • 9.3.6 India Market Size and Forecast (2021-2032)
    • 9.3.7 Southeast Asia Market Size and Forecast (2021-2032)
    • 9.3.8 Australia Market Size and Forecast (2021-2032)

10 South America

  • 10.1 South America Empagliflozin and Metformin Hydrochloride Tablets Sales Quantity by Type (2021-2032)
  • 10.2 South America Empagliflozin and Metformin Hydrochloride Tablets Sales Quantity by Application (2021-2032)
  • 10.3 South America Empagliflozin and Metformin Hydrochloride Tablets Market Size by Country
    • 10.3.1 South America Empagliflozin and Metformin Hydrochloride Tablets Sales Quantity by Country (2021-2032)
    • 10.3.2 South America Empagliflozin and Metformin Hydrochloride Tablets Consumption Value by Country (2021-2032)
    • 10.3.3 Brazil Market Size and Forecast (2021-2032)
    • 10.3.4 Argentina Market Size and Forecast (2021-2032)

11 Middle East & Africa

  • 11.1 Middle East & Africa Empagliflozin and Metformin Hydrochloride Tablets Sales Quantity by Type (2021-2032)
  • 11.2 Middle East & Africa Empagliflozin and Metformin Hydrochloride Tablets Sales Quantity by Application (2021-2032)
  • 11.3 Middle East & Africa Empagliflozin and Metformin Hydrochloride Tablets Market Size by Country
    • 11.3.1 Middle East & Africa Empagliflozin and Metformin Hydrochloride Tablets Sales Quantity by Country (2021-2032)
    • 11.3.2 Middle East & Africa Empagliflozin and Metformin Hydrochloride Tablets Consumption Value by Country (2021-2032)
    • 11.3.3 Turkey Market Size and Forecast (2021-2032)
    • 11.3.4 Egypt Market Size and Forecast (2021-2032)
    • 11.3.5 Saudi Arabia Market Size and Forecast (2021-2032)
    • 11.3.6 South Africa Market Size and Forecast (2021-2032)

12 Market Dynamics

  • 12.1 Empagliflozin and Metformin Hydrochloride Tablets Market Drivers
  • 12.2 Empagliflozin and Metformin Hydrochloride Tablets Market Restraints
  • 12.3 Empagliflozin and Metformin Hydrochloride Tablets Trends Analysis
  • 12.4 Porters Five Forces Analysis
    • 12.4.1 Threat of New Entrants
    • 12.4.2 Bargaining Power of Suppliers
    • 12.4.3 Bargaining Power of Buyers
    • 12.4.4 Threat of Substitutes
    • 12.4.5 Competitive Rivalry

13 Raw Material and Industry Chain

  • 13.1 Raw Material of Empagliflozin and Metformin Hydrochloride Tablets and Key Manufacturers
  • 13.2 Manufacturing Costs Percentage of Empagliflozin and Metformin Hydrochloride Tablets
  • 13.3 Empagliflozin and Metformin Hydrochloride Tablets Production Process
  • 13.4 Industry Value Chain Analysis

14 Shipments by Distribution Channel

  • 14.1 Sales Channel
    • 14.1.1 Direct to End-User
    • 14.1.2 Distributors
  • 14.2 Empagliflozin and Metformin Hydrochloride Tablets Typical Distributors
  • 14.3 Empagliflozin and Metformin Hydrochloride Tablets Typical Customers

15 Research Findings and Conclusion

    16 Appendix

    • 16.1 Methodology
    • 16.2 Research Process and Data Source

    According to our (Global Info Research) latest study, the global Empagliflozin and Metformin Hydrochloride Tablets market size was valued at US$ 121 million in 2025 and is forecast to a readjusted size of US$ 539 million by 2032 with a CAGR of 15.3% during review period.
    In 2025, global Empagliflozin and Metformin Hydrochloride Tablets production reached approximately 830 million units.Empagliflozin and Metformin Hydrochloride Tablets are a combination oral antidiabetic medication composed of the SGLT2 inhibitor empagliflozin and the biguanide agent metformin. The drug exerts its glucose-lowering effect through a dual mechanism: on one hand, empagliflozin reduces blood glucose levels by inhibiting renal glucose reabsorption and promoting urinary glucose excretion; on the other hand, metformin lowers blood glucose primarily by suppressing hepatic glucose production and improving insulin sensitivity. The combination provides a synergistic effect in glycemic control, while also offering benefits in weight management and cardiovascular outcomes. It is widely used for the management of patients with type 2 diabetes mellitus, particularly those with inadequate control on monotherapy.
    Empagliflozin and Metformin Hydrochloride Tablets, as a fixed-dose combination (FDC) of an SGLT2 inhibitor and a biguanide, are positioned within the rapidly growing oral antidiabetic drug market. With the global prevalence of type 2 diabetes continuing to rise and increasing demand for the management of cardiovascular and renal complications, therapies that offer both glycemic control and cardiorenal benefits are gaining significant attention. This product achieves synergistic glucose-lowering through a dual mechanism and offers advantages such as oral administration and improved patient compliance, gradually replacing some monotherapy or more complex combination regimens in clinical practice. Meanwhile, the growing recommendation of SGLT2 inhibitors in international guidelines is further driving market penetration. In mature markets, such combination products have become important therapeutic options, while in emerging markets, expanding insurance coverage and improved accessibility are unlocking substantial growth potential. Overall, the product is expected to maintain steady growth under the long-term trends of diabetes management and comprehensive chronic disease care.
    This report is a detailed and comprehensive analysis for global Empagliflozin and Metformin Hydrochloride Tablets market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
    Key Features:
    Global Empagliflozin and Metformin Hydrochloride Tablets market size and forecasts, in consumption value ($ Million), sales quantity (Units), and average selling prices (US$/Unit), 2021-2032
    Global Empagliflozin and Metformin Hydrochloride Tablets market size and forecasts by region and country, in consumption value ($ Million), sales quantity (Units), and average selling prices (US$/Unit), 2021-2032
    Global Empagliflozin and Metformin Hydrochloride Tablets market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (Units), and average selling prices (US$/Unit), 2021-2032
    Global Empagliflozin and Metformin Hydrochloride Tablets market shares of main players, shipments in revenue ($ Million), sales quantity (Units), and ASP (US$/Unit), 2021-2026
    The Primary Objectives in This Report Are:
    To determine the size of the total market opportunity of global and key countries
    To assess the growth potential for Empagliflozin and Metformin Hydrochloride Tablets
    To forecast future growth in each product and end-use market
    To assess competitive factors affecting the marketplace
    This report profiles key players in the global Empagliflozin and Metformin Hydrochloride Tablets market based on the following parameters - company overview, sales quantity, revenue, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Boehringer Ingelheim, Eli Lilly and Company, Lupin Limited, Kureasia Pharma, etc.
    This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
    Market Segmentation
    Empagliflozin and Metformin Hydrochloride Tablets market is split by Type and by Application. For the period 2021-2032, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
    Market segment by Type
    Immediate-release (IR)
    Sustained-release (SR)
    Market segment by Dosage Form
    Tablets
    Powder
    Market segment by Production Technology
    Innovator Drug
    Generic Drug
    Market segment by Application
    Type 2 Diabetes Mellitus
    Cardiovascular
    Renal Protection
    Others
    Major players covered
    Boehringer Ingelheim
    Eli Lilly and Company
    Lupin Limited
    Kureasia Pharma
    Market segment by region, regional analysis covers
    North America (United States, Canada, and Mexico)
    Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
    Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
    South America (Brazil, Argentina, Colombia, and Rest of South America)
    Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
    The content of the study subjects, includes a total of 15 chapters:
    Chapter 1, to describe Empagliflozin and Metformin Hydrochloride Tablets product scope, market overview, market estimation caveats and base year.
    Chapter 2, to profile the top manufacturers of Empagliflozin and Metformin Hydrochloride Tablets, with price, sales quantity, revenue, and global market share of Empagliflozin and Metformin Hydrochloride Tablets from 2021 to 2026.
    Chapter 3, the Empagliflozin and Metformin Hydrochloride Tablets competitive situation, sales quantity, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.
    Chapter 4, the Empagliflozin and Metformin Hydrochloride Tablets breakdown data are shown at the regional level, to show the sales quantity, consumption value, and growth by regions, from 2021 to 2032.
    Chapter 5 and 6, to segment the sales by Type and by Application, with sales market share and growth rate by Type, by Application, from 2021 to 2032.
    Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value, and market share for key countries in the world, from 2021 to 2026.and Empagliflozin and Metformin Hydrochloride Tablets market forecast, by regions, by Type, and by Application, with sales and revenue, from 2027 to 2032.
    Chapter 12, market dynamics, drivers, restraints, trends, and Porters Five Forces analysis.
    Chapter 13, the key raw materials and key suppliers, and industry chain of Empagliflozin and Metformin Hydrochloride Tablets.
    Chapter 14 and 15, to describe Empagliflozin and Metformin Hydrochloride Tablets sales channel, distributors, customers, research findings and conclusion.

    Buy now